According to the terms of the agreement, Valeritas will be responsible for product development, regulatory approval, quality management and manufacturing. Med Trust will take over the sales, marketing and distribution activities related to the V-Go wearable device in Austria and Germany, the companies reported.
“We are thrilled to partner with Med Trust, an established Austrian-based medical device manufacturer and multi-national distributor specializing in diabetes equipment, to bring V-Go wearable insulin delivery device to patients with diabetes who need insulin in Austria and Germany,” president & CEO John Timberlake said in prepared remarks.
“Combined, Austria and Germany have over 8 million adults with diabetes and we believe V-Go can become an important tool to help patients on insulin manage their diabetes. Our decision to partner with Med Trust was based on our strategy in choosing who we think are the most qualified distributors in each country who also share our passion in improving the health and simplifying the lives of patients with diabetes,” Timberlake added.
“Expanding our diabetes portfolio with the addition of V-Go is very exciting for us, and we look forward to offering this simple and effective insulin delivery option to patients with diabetes who need insulin in Austria and Germany,” Med Trust CEO Werner Trenker said.
Last week, Valeritas touted data from two new studies of its V-Go device in patients with Type II diabetes. The studies showed that using the V-Go device helped improve glycemic control and lower patients’ daily insulin use.